5 Takeaways From FDA's Off-Label Promotion Guidance

Law360, New York (March 5, 2014, 4:12 PM EST) -- New guidance from the U.S. Food and Drug Administration clarifies how drugmakers and device makers can avoid illicit off-label marketing when sharing scientific literature about unapproved uses of their products, scrubbing away a few more gray areas surrounding enforcement practices that carry multibillion-dollar implications. 

The FDA’s attempt to tie up loose ends comes at a tumultuous time for off-label promotion, which continues to factor into massive False Claims Act settlements while also being increasingly viewed as protected speech in some circumstances.

Here are five takeaways lawyers...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.